Literature DB >> 7577014

Grading of dysplasia.

R H Riddell1.   

Abstract

Lethal carcinomas are still found inadvertently in patients under surveillance; some may not be preceded by conventional dysplasia. However, there is a survival advantage for cancers detected endoscopically rather than symptomatically, and, therefore, by preventing them by colectomy when dysplasia first becomes apparent. It may, therefore, be unnecessary to grade dysplasia when found, for if unequivocally present, then immediate consideration of colectomy is appropriate. It is unreasonable to expect colonoscopists to rebiopsy what might be a minute patch of dysplasia that has no distinguishing features endoscopically. Aneuploidy deserves consideration as a potential marker of patients at particular risk of developing dysplasia, who might undergo more frequent colonoscopy and biopsies than those without the presence of aneuploidy. There is still considerable interobserver variability in the grading of dysplasia by pathologists; part of this may be because grading occurs around a mean, the width of the tails of this distribution curve determining interobserver variation.

Entities:  

Mesh:

Year:  1995        PMID: 7577014     DOI: 10.1016/0959-8049(95)00134-5

Source DB:  PubMed          Journal:  Eur J Cancer        ISSN: 0959-8049            Impact factor:   9.162


  8 in total

Review 1.  The management of dysplasia associated with ulcerative colitis: colectomy versus continued surveillance.

Authors:  Martin S Friedlich; Maha Guindi; Hartley S Stern
Journal:  Can J Surg       Date:  2004-06       Impact factor: 2.089

Review 2.  Biology of colorectal cancer in ulcerative colitis.

Authors:  B A Lashner; B D Shapiro
Journal:  J Gastrointest Surg       Date:  1998 Jul-Aug       Impact factor: 3.452

3.  Atractylenolide III Attenuates Angiogenesis in Gastric Precancerous Lesions Through the Downregulation of Delta-Like Ligand 4.

Authors:  Ying Gao; Jundong Wang; Maoyuan Zhao; Ting Xia; Qingsong Liu; Nianzhi Chen; Wenhao Liao; Zhongzhen Zeng; Fengming You; Jinhao Zeng
Journal:  Front Pharmacol       Date:  2022-06-30       Impact factor: 5.988

Review 4.  Cancer in inflammatory bowel disease.

Authors:  Jianlin Xie; Steven H Itzkowitz
Journal:  World J Gastroenterol       Date:  2008-01-21       Impact factor: 5.742

5.  Immunohistochemical expression of cyclin D1, cyclin E, p21/waf1 and p27/kip1 in inflammatory bowel disease: correlation with other cell-cycle-related proteins (Rb, p53, ki-67 and PCNA) and clinicopathological features.

Authors:  Elli E Ioachim; Konstantinos H Katsanos; Michael C Michael; Epameinondas V Tsianos; Niki J Agnantis
Journal:  Int J Colorectal Dis       Date:  2004-04-02       Impact factor: 2.571

Review 6.  Colon cancer screening and surveillance in inflammatory bowel disease.

Authors:  Song I Bae; You Sun Kim
Journal:  Clin Endosc       Date:  2014-11-30

Review 7.  Advanced endoscopic imaging for surveillance for dysplasia and colorectal cancer in inflammatory bowel disease: could the pathologist be further helped?

Authors:  Emanuele Sinagra; Giovanni Tomasello; Dario Raimondo; Andreas Sturm; Marco Giunta; Marco Messina; Giuseppe Damiano; Vincenzo D Palumbo; Gabriele Spinelli; Francesca Rossi; Tiziana Facella; Salvatore Marasà; Mario Cottone; Attilio I Lo Monte
Journal:  Saudi J Gastroenterol       Date:  2014 Jan-Feb       Impact factor: 2.485

8.  Inflammatory Bowel Disease Associated Colorectal Neoplasia.

Authors:  Michelle Vu; Jyh-Yau Chang; Jeremy Chen; David Q Shih
Journal:  J Gastrointest Dig Syst       Date:  2012-01-23
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.